Program
stapokibart
Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.
Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.
Drug pageStapokibart: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciencesits history only | 246 open or running | phase 3since Feb 17, 2022 | Mar 12, 2021 | Feb 2027phase 3 · NCT07106372 |
| Chengdu Kangnuoxing Biopharma,Inc.its history only | 33 open or running | phase 3since Sep 30, 2025 | Sep 30, 2025 | Dec 2026phase 3 · NCT07678931 |
| CSPC Pharmaceutical Group | 22 open or running | phase 3since Feb 27, 2023 | Feb 27, 2023 | Apr 29, 2032phase 3 · NCT06547333 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 19, 2023Named stapokibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, CM310
- Feb 27, 2023First study: phase 3 study in Moderate to Severe AsthmaFirst studyNCT05761028 · 600 planned · China
- Aug 7, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06547333 · 884 planned
Ahead
- Apr 29, 2032Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06547333
- May 2032Primary completion: phase 3 study in Moderate to Severe AsthmaNCT05761028
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06547333Pulmonary Disease, Chronic Obstructive | 3 | Not yet recruiting | Apr 29, 2032 | 884 |
| NCT05761028Moderate to Severe Asthma · China | 3 | Recruiting | May 2032 | 600 |
How it is read
Names in the registry
- “CM310”, 22 entries
- “Stapokibart”, 2 entries
- “Stapokibart injection”, 2 entries
- “Stapokibatrt”, 2 entries
- “Stapokibart Injection”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 12 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, 3 studies
- Nasal Polyps, 2 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.